Price T Rowe Associates Inc. MD Purchases 3,366 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Price T Rowe Associates Inc. MD boosted its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 12.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,228 shares of the company's stock after acquiring an additional 3,366 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.06% of Axsome Therapeutics worth $2,643,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after acquiring an additional 27,534 shares in the last quarter. Strategic Financial Concepts LLC acquired a new position in shares of Axsome Therapeutics in the 4th quarter worth approximately $2,599,000. Intech Investment Management LLC grew its holdings in shares of Axsome Therapeutics by 46.5% during the fourth quarter. Intech Investment Management LLC now owns 16,028 shares of the company's stock worth $1,356,000 after purchasing an additional 5,087 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Axsome Therapeutics during the fourth quarter worth $14,771,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Axsome Therapeutics by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock worth $27,755,000 after purchasing an additional 5,438 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft started coverage on Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price objective on the stock. William Blair reiterated an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. HC Wainwright lowered their target price on shares of Axsome Therapeutics from $200.00 to $180.00 and set a "buy" rating for the company in a report on Wednesday. Jefferies Financial Group began coverage on Axsome Therapeutics in a research note on Monday, April 7th. They set a "buy" rating and a $200.00 price target for the company. Finally, Leerink Partners increased their price objective on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a research report on Monday, February 10th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $172.14.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 22.30% of the stock is currently owned by corporate insiders.

Axsome Therapeutics Price Performance

Shares of AXSM traded down $1.10 during trading hours on Friday, hitting $107.76. 435,267 shares of the company were exchanged, compared to its average volume of 682,018. Axsome Therapeutics, Inc. has a one year low of $64.11 and a one year high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The company has a market capitalization of $5.31 billion, a PE ratio of -17.99 and a beta of 0.46. The firm has a fifty day simple moving average of $112.36 and a 200-day simple moving average of $104.40.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The business had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. As a group, sell-side analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.